COVID-19

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.cdc.gov/coronavirus/

Get the latest research information from NIH: https://www.covid19.nih.gov

Kevin M. Sweet

I am a Genetic Counselor and Clinician Researcher.

Kevin M. Sweet, M.S., L.G.C.

Ohio State University

With the rapid and ongoing developments associated with genetic testing, especially for actionable diseases such as cancer, I see ever greater need for more patient-driven approaches and direct access to genetic counselors who can help maximize the effectiveness of the genetic testing process and provide a guiding hand.

Kevin Sweet is a professor in the Division of Human Genetics at the Ohio State University Wexner Medical Center. His research program focuses on developing and evaluating alternative models of genetic counseling service delivery that capitalize on new technologies and actively accommodate a more patient-driven focus for precision health. He first became interested in alternative models of service delivery through work on a direct-to-consumer (DTC) research collaborative, which explored use of post-genetic test counseling approaches and patient preferences. He is also passionate about development and use of automated family history risk assessment tools for the general public and for patient care, and the application of implementation science to better advance health equity.

His current R01 is a randomized controlled trial that leverages a genetic counseling patient preference (GCPP) intervention via an electronic health record (EHR) portal to actively engage women at elevated breast cancer risk. Since approximately 96% of U.S. hospitals utilize EHRs, there is great potential for the GCPP intervention to reach rural and underserved patient populations. The study is also innovative in providing comprehensive assessment to patients at elevated breast cancer risk with use of multigene panels and validated polygenic risk score (PRS). PRS have not been a part of previous models used in genetic counseling for breast cancer screening recommendations. Study results may change how genetic counseling is delivered and address the increasing genetic counseling workforce burden.




To request edits to this profile, please contact Mark Alexander at alexandm@mail.nih.gov.

Last Updated: 01/27/2021 08:50:34